A groundbreaking shift in Canadian drug policy has happened, as the regulators announce the use of psilocybin hallucinogens for therapeutic applications. Before this, these substances were heavily restricted, but a mounting body of studies suggests they may offer benefits for mental health illnesses like depression. This development represents a ma